The pipeline for novel antimicrobial agents among the world’s largest pharmaceutical companies contracted by 35% over the past five years, declining from 92 candidate treatments to 60, according to a new analysis that amplifies longstanding concerns about the adequacy of the global response to antimicrobial resistance (AMR). The findings point to structural disincentives that continue to suppress private sector investment in antibiotic development, with particular deficiencies observed in pediatric formulations and access across sub-Saharan Africa.

The analysis arrives at a moment when infectious disease specialists and public health authorities have grown increasingly vocal about the mismatch between the clinical urgency of drug-resistant infections and the commercial conditions under which pharmaceutical manufacturers operate. Antimicrobial resistance already contributes to an estimated 1.27 million deaths annually, a figure the World Health Organization (WHO) projects will rise substantially in the absence of coordinated intervention at both the policy and pipeline level.

A Thinning Pipeline

The reduction from 92 to 60 active antimicrobial development programs among major pharmaceutical companies represents a contraction that, by any measure, moves in the wrong direction relative to the WHO’s bacterial priority pathogen list. That list, which the WHO maintains to direct research and development investment toward organisms of greatest clinical threat, identifies pathogens including carbapenem-resistant Acinetobacter baumannii, extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae, and drug-resistant Mycobacterium tuberculosis, among others.

Of the 39 antimicrobial pipeline projects the analysis identified as specifically targeting WHO priority pathogens, only five, representing 13% of that subset, are being developed for use in children under five years of age. All five of those candidates have already received regulatory approval for use in adult populations. The process of securing separate approval for pediatric indications has taken several years in each case, and two approvals remain pending.

That gap between adult and pediatric indication approval is not merely a regulatory inconvenience. Sepsis and pneumonia caused by drug-resistant organisms disproportionately affect neonates and young children in low- and middle-income countries. A pipeline that produces effective agents for adults but leaves pediatric dosing formulations undeveloped, or leaves pediatric regulatory submissions years behind adult approvals, creates a structural delay in access for the populations bearing some of the highest burden of these infections.

Why Large Companies Are Withdrawing

The commercial logic driving pharmaceutical companies away from antibiotic development is well-documented and has been analyzed extensively in health economics literature. Antibiotics, when effective, are prescribed for short courses. Stewardship programs, which are clinically necessary to slow resistance development, deliberately limit utilization. A novel antibiotic that successfully treats carbapenem-resistant infections may, in practice, be reserved as a last-line agent, prescribed to a relatively small number of patients per year, and thus generate modest revenue regardless of its clinical value.

This stands in sharp contrast to treatments for chronic conditions such as diabetes, cardiovascular disease, or oncologic indications, where long-term or maintenance therapy generates predictable revenue streams. Large pharmaceutical companies operate under obligations to shareholders that make sustained investment in low-return therapeutic categories structurally difficult, absent policy intervention.

Several mechanisms have been proposed to address this misalignment, including transferable exclusivity vouchers, subscription-based payment models that decouple revenue from volume of use, and advance market commitments modeled on those deployed for vaccines. The United Kingdom has piloted a subscription model with a small number of novel antibiotics. The United States enacted the PASTEUR Act framework in prior legislative cycles, though full implementation and funding have proceeded unevenly.

The new analysis suggests that these interventions, to the extent they have been implemented, have not yet reversed the trajectory of large-company pipeline contraction. Smaller biotechnology companies and academic institutions continue to conduct early-stage antimicrobial research, but the transition of candidates through late-stage clinical development and commercialization typically requires the capital and infrastructure that larger companies possess.

The Pediatric Formulation Gap

The specific deficit in pediatric antimicrobial development merits attention beyond its reflection in pipeline statistics. Regulatory frameworks in both the United States and the European Union have historically required that sponsors submit pediatric investigation plans or pediatric study requirements for new drug applications, with certain exemptions. Despite these requirements, the gap between adult approval and pediatric approval for antimicrobial agents has persisted.

Pediatric formulation development introduces technical challenges distinct from those encountered in adult trials. Weight-based dosing, palatability of oral formulations, pharmacokinetic variability across age groups, and the ethical and logistical complexities of conducting clinical trials in neonates and young children all contribute to the lag. Sponsors may satisfy regulatory requirements for pediatric data submission while the actual availability of an approved pediatric formulation remains years away.

The analysis notes that of the five pipeline candidates in development for children under five, all represent agents already navigating a secondary approval pathway following initial adult approval. No candidate in the analyzed pipeline appeared to have pursued pediatric development as a primary or co-primary regulatory objective. This sequencing reflects rational commercial prioritization but results in a systematic deferral of access for pediatric patients.

Access Deficits in Sub-Saharan Africa

Among the most consequential observations in the analysis is the near-complete absence of registered pediatric antimicrobial formulations across 17 sub-Saharan African countries examined. None of the pharmaceutical companies whose pipelines were assessed had registered pediatric formulations of their antimicrobial products in these countries.

This finding is notable in part because it cannot be attributed entirely to regulatory barriers. The analysis documented that these same companies had registered other pharmaceutical products in 10 of the 17 countries in question. The selective non-registration of pediatric antimicrobial formulations therefore reflects, at least in part, a commercial decision rather than an insurmountable regulatory obstacle.

Sub-Saharan Africa carries a disproportionate burden of pediatric infectious disease mortality. Neonatal sepsis, community-acquired pneumonia, and invasive bacterial infections caused by drug-resistant organisms represent leading causes of under-five mortality across much of the region. The clinical need for registered, appropriately formulated pediatric antimicrobials is acute. The documented absence of registration activity by major manufacturers, in countries where those manufacturers have demonstrated the capacity to register other products, represents a consequential gap between commercial incentive and public health necessity.

Regulatory harmonization efforts, including those supported by the African Medicines Agency (AMA), have sought to reduce the duplicative country-by-country registration burden that can deter registration in lower-volume markets. Progress has been incremental. The analysis does not resolve the question of whether expanded registration activity would follow from harmonization, or whether the absence of a viable commercial market would continue to suppress registration irrespective of regulatory simplification.

Implications for Hawaii and the Pacific Region

Hawaii’s geographic position as a hub for transpacific travel and as a health care referral center for Pacific Island communities places the state at particular interface with AMR trends that originate in Southeast Asia, the Pacific Islands, and the broader Indo-Pacific region. The Hawai’i Department of Health and clinical institutions including The Queen’s Medical Center and Hawaii Pacific Health system have documented cases of carbapenem-resistant Enterobacteriaceae (CRE) and methicillin-resistant Staphylococcus aureus (MRSA) strains in patients presenting from regional island communities where local diagnostic and treatment infrastructure is limited.

A contracting global pipeline for novel antimicrobials, combined with persistent gaps in pediatric formulation access, compounds the clinical challenges faced by providers managing drug-resistant infections in populations that may have limited prior exposure to robust antimicrobial stewardship programs. Pediatric patients transferred to Honolulu facilities from Micronesian or Polynesian communities may present with infections for which the available treatment options are already constrained, and for which newly approved agents may not yet carry approved pediatric indications.

These dynamics underscore the relevance of pipeline adequacy not as an abstraction, but as a determinant of the therapeutic options available to individual clinicians managing individual patients.

What the Analysis Does Not Resolve

The analysis, as summarized in available reporting, documents the scale of pipeline contraction and equity gaps with considerable specificity. It does not fully resolve several questions of ongoing policy relevance. Whether the pull incentive mechanisms currently under consideration or partial implementation in the United States, United Kingdom, and European Union are sufficient in magnitude to reverse large-company withdrawal from antibiotic development remains an open question. Whether the smaller biotechnology companies that constitute a growing share of early-stage antimicrobial research can successfully transition candidates through late-stage development without acquisition or partnership with larger manufacturers is similarly uncertain.

The 13% rate of pediatric coverage among priority pathogen pipeline candidates suggests that even if the overall pipeline were to stabilize or grow, the pediatric gap would persist unless sponsors adopt deliberate strategies to pursue pediatric indications concurrently with adult development programs. Regulatory incentives exist for this approach but have not produced the result the analysis describes.

Public health authorities, regulatory bodies, and legislative actors across multiple jurisdictions have acknowledged these dynamics for more than a decade. The current analysis adds quantitative specificity to a pattern that